Namalwa

We conducted a prospective randomized phase 3 trial in MM at first relapse comparing the activity of bortezomib, cyclophosphamide, and dexamethasone versus lenalidomide, cyclophosphamide, and dexamethasone as secondline therapy. Within this study, 25 patients who achieved complete response during therapy (International Myeloma Working Group guidelines) 9 and had longitudinal biological samples collected for disease monitoring were analyzed. Our institutional review board approved this study (INT 57/ 10), and patients provided informed consent.
BM and PB samples were obtained during routine clinical evaluations at study entry; after 3, 6, and 9 cycles of therapy; and at follow-up time points. Plasma was obtained processing PB samples collected in K2-EDTA tubes (BD Vacutainer, Becton Dickinson, Franklin Lakes, NJ) within 3 hours, with a first centrifugation at 1500 Â g for 10 minutes and a second high-speed centrifugation at 16,000 Â g for 10 minutes at 4 C. Plasma samples were stored at À80 C until extraction. 10 PB of 10 healthy donors was also collected. Namalwa (human Burkitt lymphoma; ACC 24) and JVM-2 (human chronic B-cell leukemia; ACC 12) cell lines were from DSMZ (Braunschweig, Germany).